Menu
← Oncology Approval Tracker
FDA DECISION ·
Gomekli
mirdametinib · SpringWorks Therapeutics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults and children age 2 years or older with neurofibromatosis type 1 and symptomatic plexiform neurofibromas that cannot be fully removed surgically.
LAMPGEN ANALYSIS
Why it matters
This MEK inhibitor targets symptomatic benign nerve sheath tumors in both children and adults.
What research teams should watch
Plan baseline and follow-up imaging, ophthalmology, and cardiac assessments across pediatric and adult services.
PRIMARY RECORDS